Important information for Sandringham Hospital maternity, newborn and gynaecology patients. Find out more.

Contact About Find a doctor Careers The Alfred Foundation For staff

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Clear filter

665 clinical trials found

Clinical trials

FIBRONEER™-ON

An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis [IPF] and progressive pulmonary fibrosis [PPF] [FIBRONEER™-ON] (NCT06238622)

No longer recruiting

FILGOTINIB 3899

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis (NCT02914535)

Currently recruiting

FINER

A Double- Blinded Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced/ Metastatic Her 2 Negative and Oestrogen Receptor Positive (ER+) Breast Cancer following Progression on first line CD4/6 Inhibitor and Aromatase Inhibitor (Finer) (NCT04650581)

No longer recruiting

FIRMS EBV

Fatigue In Relapsing Multiple Sclerosis Epstein-Barr Virus Treatment Trial (ACTRN12624000423516)

A clinical trial assessing the impact of tenofovir alafenamide, spironolactone and placebo on fatigue in people with MS over a period of 16 weeks. Aiming to reduce the frequency of the Epstein Barr Virus DNA in saliva and improve participant reported outcome measures of disease compared to placebo.

Coming soon

FLAP ATTACK

Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries (NCT06293469)

Currently recruiting

FLASH

Fludrocortisone administration in aneurysmal subarachnoid haemorrhage (NCT06409364)

A multi-centre, prospective, blinded, randomised clinical trial of fludrocortisone compared with placebo in patients presenting with aneurysmal subarachnoid haemorrhage.

The study aim is to determine if early administration of enteral fludrocortisone in aneurysmal subarachnoid haemorrhage reduce death and dependency at six months.

Currently recruiting

FMT-CHECKPOINT

A Pilot Study of the Efficacy and Safety of Faecal Microbiota Transplant for the Treatment of Immune Checkpoint Inhibitor Colitis (ACTRN12624000120572)

Currently recruiting

FORMaT

A multi-centre, randomised, multi-arm, adaptive platform trial in people with or without cystic fibrosis Finding the Optimal Regimen for Mycobacterium abscessus Treatment [FORMaT] (NCT04310930)

Currently recruiting

FORTE F8394-201

A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations (NCT05503797)

Currently recruiting

Forward-FMGX-CS-302 -PSI

An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, (NCT06925321)

The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections. The study is looking for patients who have been diagnosed with invasive mold infections. The maximum study duration will be approximately 8 months, including a target study treatment duration of 84 days which can be extended up to 180 days and follow-up period. The patient will be assigned to one of two treatment cohorts: Cohort A (primary therapy): Patients will receive either the study drug or institutional standard of care antifungal treatment. Cohort B (salvage treatment; i.e. treatment given after patients did not respond to previous treatments or did not tolerate them): Patients will receive the study drug The primary aim is to compare the all cause mortality with a fixed threshold at Day 42.

Currently recruiting

FpA-AS-30094

A randomised, double-blind, multicentre, Active-controlled, parallel-group study to evaluate the efficacy and safety of fluticasone proprionate/alburterol sulfate fixed-dose combination on severe asthma exacerbations in patients with Asthma (NCT06052267)

Currently recruiting

FRAIL-AS

Frailty response in patients with aortic stenosis undergoing transcatheter aortic valve implantation; a cluster randomised controlled trial (ACTRN12624000318583)

Currently recruiting

FRAIL-M

Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study (ACTRN12619001199101)

No longer recruiting

FRONTIER-AP

FRONTIER-AP: Randomized controlled trial of endovascular versus standard medical therapy for stroke with medium sized vessel occlusion (ACTRN12621001746820)

Currently recruiting

GAIN

An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants with Parkinson’s Disease With or Without a Pathogenic GBA1 Mutation (NCT06732180)

Currently recruiting

Gamegear in Australian Collision Sports

Concussion Incidence with Gamegear Nodal Impact Attenuation Headgear: A Multistate Randomised Crossover Clinical Trial in Australian Collision Sports (Trial Not Registered)

This study is investigating whether a soft protective headgear may reduce concussion rates or severity in Australian amateur football and rugby players. Participants will play matches with and without the headgear following an alternating schedule, and some players will also wear a mouthguard that measures head impacts. The study will compare concussion outcomes and head impact data across the season.

Coming soon

GB261-001

A Phase I/II, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GB261 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (GB261-001) (NCT04923048)

Currently recruiting

GCT3013-03/EPCORE CLL-1

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome (NCT04623541)

Currently recruiting

GENENTECH GO39775

An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of Cevostamab (BFCR4350A) in patients with relapsed or refractory multiple myeloma (NCT03275103)

Currently recruiting

GENMAB GCT3014-01

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies (NCT04824794)